<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646994</url>
  </required_header>
  <id_info>
    <org_study_id>CORE</org_study_id>
    <nct_id>NCT03646994</nct_id>
  </id_info>
  <brief_title>Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer</brief_title>
  <official_title>A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ROS1-rearranged Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to explore the efficacy and safety of Crizotinib as a first-line
      treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world,
      explore the new drug resistance mechanism of ROS1 under Crizotinib treatment and the
      consistency of plasma and tissue detection driving genes, and finally evaluate the mutation
      spectrum of plasma dynamic detection driving genes. In predicting the risk of disease
      progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a research project involving patients in Medical Oncology Department of Affiliated
      Cancer Hospital of Xiangya School of Medicine Central South University. Retrospective study
      of 40 patients with advanced non-squamous non-small cell lung cancer (NSCLC) using Crizotinib
      ROS1 rearrangement positive mutation was conducted to observe the efficacy and safety of
      Crizotinib regimen in the real world.Exploratory research contents are as follows: 1.
      Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the initial
      diagnosis; 2. Consistency between NGS and plasma gene test (NGS) at the progression of
      clozotinib treatment; 3. Drug resistance mechanism of clozotinib in ROS1 rearrangement
      positive NSCLC; 4. Plasma drug resistance. Large panel dynamic driven gene mutation analysis
      was used to construct disease progression risk model.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>may 2018- may 2019 (1 year)</time_frame>
    <description>progression survival time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>may 2018- may 2019 (1 year)</time_frame>
    <description>objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>may 2018- may 2019 (1 year)</time_frame>
    <description>over survival time</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohorts 1</arm_group_label>
    <description>ROS1 fusion positive NSCLC patients who received crizotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Crizotinib Cap 250 mg po bid</description>
    <arm_group_label>Cohorts 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue sample and plasma DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ROS1 rearranged Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by NGS
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology

          -  ROS1 Arranged Positive

          -  ROS1 Arranged Detection Method is NGS

          -  First Diagnosis and Treatment

          -  Treatment Plan is Kazolinib 250mg po bid

        Exclusion Criteria:

          -  Patients received antitumor treatment before

          -  Patients with contraindication of chemotherapy

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongchang Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongchang Zhang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>7+861383123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nong Yang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>+8613873123436</phone_ext>
    <email>yangnong0217@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762323</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Nong Yang, MD</last_name>
      <phone>+86 731 89762321</phone>
      <email>yangnong0217@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Crizotinib</keyword>
  <keyword>ROS1 Rearranged</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

